Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

Table 5 Differences in total healthcare costs between different Interferon Beta formulations

Monthly costs:	Avonex®	Betaferon®	Extavia®	Plegridy®	Rebif®
Overall costs (€)	799.25 ± 287.98	465.75 ± 138.81	533.54 ± 339.93	824.75 ± 416.42	901.39 ± 441.48
Coeff	− 92.74	− 430.00	− 397.05	−99.00	reference
95%CI	137.38, −48.09	−467.04, − 392.97	− 474.24, − 319.87	− 175.96, −22.03
p-value	< 0.01	< 0.01	< 0.01	0.01
DMT costs (€)	778.11 ± 283.90	448.57 ± 132.35	506.94 ± 329.90	822.88 ± 416.14	881.86 ± 431.02
Coeff	−94.99	− 419.33	− 411.00	−72.88	reference
95%CI	−137.38, −52.59	− 453.51, − 385.15	− 472.49, − 349.51	− 148.48, 2.71
p-value	< 0.01	< 0.01	< 0.01	0.06
Outpatient costs (€)	0.95 ± 3.19	0.82 ± 1.61	0.79 ± 1.83	0.28 ± 1.67	0.69 ± 1.94
Coeff	0.46	−0.05	0.17	−0.68	reference
95%CI	0.00, 0.93	−0.35, 0.24	− 0.60, 0.96	−1.15, 0.22
p-value	0.04	0.72	0.65	0.83
Inpatient costs (€)	20.19 ± 65.11	25.35 ± 44.31	25.80 ± 111.22	1.87 ± 0.94	18.84 ± 8.80
Coeff	1.78	10.62	13.77	−25.43	reference
95%CI	−10.87, 14.43	0.97, 22.21,	−35.72, 63.25	−37.28, − 13.59
p-value	0.78	0.04	0.58	< 0.01

Table shows monthly costs for different Interferon Beta formulations, and, then, specific costs for DMTs, MS-related outpatients and inpatients. Coeff, 95%CI, and p-values are reported from mixed effect linear regression models adjusted by age, sex, and treatment duration (Rebif® was used as reference in the statistical models)

ISSN: 1472-6963